A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists ...

"In the case of oral semaglutide for overweight/obesity, it appears that 25 mg a day is that dose." The trial enrolled 243 participants with a BMI of at least 30, or 27 with a weight-related ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

In 2021, the FDA approved of another injectable semaglutide, Wegovy, for chronic weight management in adults with obesity/overweight and with at least one weight-related condition (such as high ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

About The Study: Among patients with alcohol use disorder (AUD) and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of ...